Heron Therapeutics, Inc. (HRTX) company profile
Close on Nov 17, 2026Market cap $53.58MP/E –Yield –
About Heron Therapeutics
Pharmaceutical Preparations, SIC 2834
The company is a commercial-stage biotechnology firm focused on developing and commercializing therapeutic products for acute care and oncology patients. Its acute care product line includes ZYNRELEF, a dual-acting extended-release local anesthetic combining bupivacaine and meloxicam for postoperative pain management, and APONVIE, an intravenous formulation of aprepitant used to prevent postoperative nausea and vomiting. Its oncology offerings consist of CINVANTI and SUSTOL, which are injectable therapies designed to prevent acute and delayed chemotherapy-induced nausea and vomiting. The company markets these treatments in the United States through specialty distributors and full-line wholesalers that supply healthcare providers and hospital systems.
The company operates primarily within the United States, maintaining a domestic sales and marketing team of 78 employees as of December 31, 2025. It does not own or operate manufacturing facilities, depending on third-party contract manufacturers for the production of clinical and commercial supplies. The provided excerpt does not state the location of the company's corporate headquarters.
Summary of the business section of Heron Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Heron Therapeutics, Inc.
- Headquarters
- San Diego, CA
- Address
- 4242 Campus Point Court, Suite 200 92121
- Phone
- (858) 251-4400
- Website
- herontx.com
- Employees
- 128, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- WithumSmith+Brown, PC, Orlando, Florida
Stock & identifiers
- Ticker
- HRTX
- Exchange
- Nasdaq
- IPO date
- Aug 26, 1987
- Shares outstanding
- 190M, Aug 5, 2026
- Public float
- $235.10M, Jun 30, 2025
- Filer category
- Accelerated filer
- Stock splits
- 1-for-20 reverse, Jan 13, 2014; 1-for-4 reverse, May 25, 2007
- SEC CIK
- 818033
- CUSIP
- 427746102
- ISIN
- US4277461020
- FIGI
- BBG000G2GJT7
- Share class FIGI
- BBG001SB92D4
- LEI
- 549300DR2I1DOPD2IX53
- EIN
- 94-2875566
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Craig A. Collard | Chief Executive Officer, Director | 931,086 |
| Mark Earl Hensley | Chief Operating Officer | 201,683 |
| William P. Forbes | EVP, Chief Development Officer | 260,734 |
| Ira Duarte | EVP, Chief Financial Officer | 302,724 |
| Thomas Cusack | Director | 53,960 |
| Michael Kaseta | Director | 53,960 |
| Craig A. Johnson | Director | 53,960 |
| Sharmila Dissanaike | Director | 53,960 |
| Adam Morgan | Director | 8,877,027 |
| Waage Christian | Director | 53,960 |
| Susan Rodriguez | Director | 87,180 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $3.52M | $2.02M | $2.54M | $6 | $120 |
| FY2024 | $3.40M | $3.47M | $1.48M | $7 | $91 |
| FY2023 Barry Quart | $4.03M | $836.46K | $1.62M | $8 | $92 |
| FY2023 Craig Collard | $10.78M | $10.87M | $1.62M | $8 | $92 |
| FY2022 | $1.15M | -$2.80M | $1.44M | $12 | $89 |
| FY2021 | $5.43M | -$1.03M | $1.58M | $43 | $99 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Craig Collard Chief Executive Officer | $689.43K | $946.25K | $1.35M | $517.19K | $10.50K | $3.52M | +4% |
| Ira Duarte EVP, Chief Financial Officer | $559.80K | $318.09K | $454.79K | $287.50K | $10.50K | $1.63M | +14% |
| William Forbes EVP, Chief Development Officer | $609.88K | $318.09K | $454.79K | $305.01K | – | $1.69M | +10% |
| Mark Hensley EVP, Chief Operating Officer | $372.21K | $1.21M | $2.53M | $187.11K | $10.50K | $4.31M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 128 full-time employees, 78 of whom are involved in sales and marketing activities, 7 of whom are involved in research and development activities and 43 of whom are involved in general and administrative activities.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?